BioNTech to support trial access for cancer immunotherapies
Signing of a major agreement between BioNTech SE and the UK government for cancer trials means more patients could access personalised immunotherapies.
List view / Grid view
Signing of a major agreement between BioNTech SE and the UK government for cancer trials means more patients could access personalised immunotherapies.
A paper has shown how machine learning (ML) models predicted the inkjet printing printability of drug formulations with high accuracy.
The new Clinical Biotechnology Centre (CBC) in Bristol will manufacture cell and gene therapies to help boost the UK life sciences sector.
The role of personalised and precision medicine may be ideal for the treatment of cancer, but questions about consequences and society issues still remain...
A statistical model has been developed to calculate the success of drugs for individuals, which could lead to the availability of precision medicine...